Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 10, 2026
- Autolus Therapeutics plc reported third-quarter AUCATZYL net product revenue of $41.2 million, up 95% year-over-year, and now expects 2026 revenue at or exceeding the upper end of $150 million.
- 10-Q report · filed Nov 10, 2026
- Autolus Therapeutics reported AUCATZYL revenue of $41.2 million for the three months ended September 30, 2026, versus $21.1 million, as net loss narrowed to $55.1 million from $79.1 million. Cash and cash equivalents totaled $245.4 million.
The audio replay and transcript follow the call.